Andean highlanders adapt to thin air through epigenetic gene tuning, revealing a flexible, long-term path to altitude survival.
A placebo-controlled trial has shown that the oral AKT inhibitor engasertib could reduce the frequency and duration of ...
Ipatasertib showed significant activity in patients with AKT1E17K mutations, with a 24.1% objective response rate and a median response duration of 10.1 months. The trial's 6-month progression-free ...
DNA sequencing technology makes it possible to explore the genome to learn how humans adapted to live in a wide range of ...
An aggressive breast cancer lacking common drug targets, triple-negative breast cancer may be countered by oridonin, a ...
A team of researchers from the Germans Trias i Pujol Research Institute (IGTP) and Institut Català d'Oncologia (ICO) has ...
A clinical trial of Vaderis Therapeutics' AKT inhibitor engasertib suggests it could be the first effective treatment for ...
Circadian rhythms are endogenous oscillations widely present in living organisms, typically following approximately 24-hour ...
For more details about SABCS please visit: https://www.sabcs.org/.
MINNEAPOLIS, Nov. 26, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced its ...
Selinexor-based regimens enhance T-cell activation in RRMM patients, without increasing inhibitory checkpoint molecules, indicating resistance is not due to T-cell exhaustion. Baseline protein ...
Psoriasis, a chronic inflammatory skin disease, relies heavily on abnormal angiogenesis for its pathogenesis, and AlkB ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback